Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. - Wikidata - wikimedia - TriplyDB

Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation.

Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation.

http://www.wikidata.org/entity/Q41564280

about

Management of hepatitis c genotype 4 in the liver transplant setting Treatment strategies for chronic hepatitis C prior to and following liver transplantation Liver transplantation for viral hepatitis in 2015 Role of liver transplantation in human immunodeficiency virus positive patients Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review Impact of new treatment options for hepatitis C virus infection in liver transplantation Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients Hepatitis C cirrhosis: New perspectives for diagnosis and treatment Changing the face of hepatitis C management - the design and development of sofosbuvir Anti-hepatitis C virus drugs and kidney Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection Fibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantation The Impact of Infection on Chronic Allograft Dysfunction and Allograft Survival After Solid Organ Transplantation Hepatitis C virus infection.The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma.Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015 Long-term outcomes of heart transplant recipients with hepatitis C positivity: the data from the U.S. transplant registry.Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.Hepatitis C Virus and Liver Transplantation.Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates Efficacy and safety of sofosbuvir-based interferon-free therapies for hepatitis C in liver transplant recipients.Severe Cholestatic Hepatitis C in Transplant Recipients: No Longer a Threat to Graft Survival.Use of Hepatitis C-Positive Donor Livers in Liver Transplantation.Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation.New perspectives for preventing hepatitis C virus liver graft infection.Safety, Efficacy, and Tolerability of Sofosbuvir and Ribavirin in Management of Recurrent Hepatitis C Virus Genotype 4 After Living Donor Liver Transplant in Egypt: What Have We Learned so far?Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.Liver Support With Albumin Dialysis Reduces Hepatitis C Virus Viremia and Facilitates Antiviral Treatment of Severe Hepatitis C Virus Recurrence After Liver Transplantation.Hepatitis C virus and liver transplantation: where do we stand?Advances in hepatitis C therapies.Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection.Impact of hepatitis C virus infection on health-related quality of life before and after liver transplantation: a multidisciplinary point of view.News and challenges in the treatment of hepatitis C in liver transplantation.The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation.The future of liver transplantation for viral hepatitis.

P2860

Q26749326-3749E8F7-20F7-4086-891A-2D65D03968E3 Q26771244-43775F93-D0D7-4382-BEFB-B49913BEAB68 Q26773224-E29534AB-EB32-4B7E-8F0A-67AF1E2B829D Q26775931-F5E09BDF-8B07-44E1-B292-9055DB7F9F10 Q26781331-D923A1D1-52B0-4F4B-969A-594091C34627 Q26781741-3F956F94-B672-46D4-838D-83640C50B48A Q26782017-5316944B-8201-4BA3-BB73-9DFB291FF015 Q26795595-E4086CD0-4929-4268-88A7-84EA1BF56184 Q26799924-FA729469-460B-4590-BEDB-85ABC51342BE Q27011203-C5C9F887-49F1-4A31-8295-1750477E4BFD Q28070279-57B09A7C-C9EC-4DF3-9608-C8F8C429D9A5 Q28075544-23F4ED5A-D036-4D4C-A16F-8E8717BBA263 Q28076406-3945376C-E3C7-417E-9AC4-8D0756FBFA20 Q28085440-EAA571D6-CCBB-427C-89B7-7B606DAF0B05 Q30235491-5DB3A817-46A5-4326-8298-313443BBE1EC Q30250096-108B37C5-DC44-41DD-BBA4-A5AB37D68600 Q30355190-6F04C2EC-2802-444A-9837-4167BBF229D4 Q30375305-D643F3F6-16C1-4D78-9C1E-FE949B917823 Q31136569-2FC4F7BB-BD3E-4C8E-86E3-110576336648 Q33435950-018A7D02-8FFF-47D9-94A6-6095953A5002 Q33717116-4D724DB2-119E-46B6-A5D1-4750C07868E2 Q35790393-BC10AD68-506C-450D-9829-DD05866C5145 Q35901512-91EA30A4-4289-4332-BA48-BA8CCE832C7B Q36165389-7AA37450-71C4-4DB7-9E67-2B6546ED5153 Q36190835-17B94356-BB78-4F7B-9D22-0B1F9580EF1D Q36292616-2F568C29-EB29-4898-8F61-02624BB47FA5 Q36650834-D8BCEEFC-53D2-4579-B16C-DBFAB58847D1 Q36990362-CFDFF2A2-24AA-45C5-98AE-56E36B863B2D Q37015805-298C3039-4E22-4F7C-8630-C271EE5C1A93 Q37017909-98B3DD10-F84B-44D1-9B7B-7747BFD374CE Q37552703-AE6290B7-A092-4960-8BFE-83C0921A0F03 Q38439220-DA66C626-D44F-452B-9E14-A7A145186888 Q38551818-D10CEFC3-42C5-4F04-B276-E5A333B8F8D8 Q38556401-98D82A1B-D1B8-4375-B773-FB90F59B289D Q38602682-0AEC10A6-AAB3-469E-AFC3-4C78CC397BDC Q38630475-A4EA5C8E-4289-4321-A25D-5BB7D8C1343F Q38653173-5508EEEA-6DFD-4F6E-B651-509498FC3176 Q38685574-64F270C4-6ADA-468D-9C33-28315E4FBAF8 Q38757351-AFA55E62-4955-4999-86A6-6ADE3DBB6B2C Q38774864-8E63EAFF-9A6A-45EB-BDF2-38005F8E9750

P2860

Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation.

http://www.wikidata.org/entity/Q41564280

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Sofosbuvir compassionate use p ...... C after liver transplantation.

@en

type

label

Sofosbuvir compassionate use p ...... C after liver transplantation.

@en

prefLabel

Sofosbuvir compassionate use p ...... C after liver transplantation.

@en

P1433

Q41564280-9DF953AF-12E6-4202-A5E9-5E9061C4DB34

P1476

Q41564280-DA9D1430-E5D6-499D-B2F9-F5EAD3991E9C

P2093

Q41564280-17BBF330-1164-4841-866F-274817BF8333

Q41564280-386C0F0E-4B5C-4E9D-AA63-268B7F78DDAB

Q41564280-4A946422-6963-411C-AFE7-EFA47DD57024

Q41564280-5C0ABA36-7543-465E-8A7E-08C0AFA84E76

Q41564280-6CF78B6C-29F9-45F7-9919-7DE32C3C58D4

Q41564280-83B9D7A1-661E-47A4-BBCD-125A768456DB

Q41564280-851F14BE-45A9-4E31-B9E3-66BF19134788

Q41564280-85B45501-ABE3-49AB-914E-232BA0875940

Q41564280-93D23AAC-D002-4E30-96F6-BE914C865E85

Q41564280-A75B446F-EB53-4413-8397-574DF807D101

P304

Q41564280-5AEC5923-9A38-43C6-8857-7A33CEAF68B1

P31

Q41564280-6417250A-C244-43D8-BCFD-DDCAD71AD2BB

P356

Q41564280-3263D4B2-3D65-4559-9FB9-4CB095C6D5D0

P407

Q41564280-51CEFF8F-0391-45FD-BF13-D4743E85E4E0

P433

Q41564280-25D63698-3B51-4E13-A543-A33CA998BCE5

P478

Q41564280-9188321C-0F96-46A2-8AC9-351CFD4CE771

P50

Q41564280-29ED8741-69C1-4BA9-A380-88BBBD122DC3

P577

Q41564280-28F1D530-6ED3-4EE5-BD54-1F88A2495528

P698

Q41564280-84CF6819-E31C-46E7-B259-39D26961ACEF

P921

Q41564280-27568C11-82C6-4557-9AA6-5D2C39DCFB9D

Q41564280-5FF53AAB-D4A9-446F-8A49-0D182A48822A

P356

P1433

P1476

Sofosbuvir compassionate use p ...... C after liver transplantation.

@en

P2093

Audrey Coilly

http://www.w3.org/2001/XMLSchema#string

Diana Brainard

http://www.w3.org/2001/XMLSchema#string

François Habersetzer

http://www.w3.org/2001/XMLSchema#string

Jill Denning

http://www.w3.org/2001/XMLSchema#string

John G McHutchison

http://www.w3.org/2001/XMLSchema#string

Maria Carlota Londoño

http://www.w3.org/2001/XMLSchema#string

Martín Prieto

http://www.w3.org/2001/XMLSchema#string

Michael Charlton

http://www.w3.org/2001/XMLSchema#string

Paul Chang

http://www.w3.org/2001/XMLSchema#string

Robert J Fontana

http://www.w3.org/2001/XMLSchema#string

P304

1485-1494

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.27681

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P50

Lluís Castells

P577

2015-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25557906

http://www.w3.org/2001/XMLSchema#string

P921

liver transplantation